These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 20186933)
1. Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a. Rodrigues S; Magro F; Soares J; Nunes AC; Lopes S; Marques M; Rio E; Macedo G Inflamm Bowel Dis; 2010 Dec; 16(12):2001-3. PubMed ID: 20186933 [No Abstract] [Full Text] [Related]
2. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718 [TBL] [Abstract][Full Text] [Related]
3. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis. Tuna Y; Başar O; Dikici H; Köklü S J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812 [No Abstract] [Full Text] [Related]
4. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
5. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Mannon PJ; Hornung RL; Yang Z; Yi C; Groden C; Friend J; Yao M; Strober W; Fuss IJ Gut; 2011 Apr; 60(4):449-55. PubMed ID: 20971977 [TBL] [Abstract][Full Text] [Related]
6. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept]. Kornhuber ME; Zierz S Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792 [No Abstract] [Full Text] [Related]
7. Lessons from type I interferons in ulcerative colitis. Kaser A; Blumberg RS Gut; 2011 Apr; 60(4):430-1. PubMed ID: 21266724 [No Abstract] [Full Text] [Related]
10. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region]. Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035 [TBL] [Abstract][Full Text] [Related]
11. Interferon treatment for multiple sclerosis patients in Hong Kong. Lau KK; Lee PO; Chan KY; Chan YW; Chin KF Hong Kong Med J; 2000 Jun; 6(2):221-3. PubMed ID: 10895148 [TBL] [Abstract][Full Text] [Related]
12. Can we get rid of neutralizing antibodies against interferon-β? Buttmann M; Toyka KV Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143 [No Abstract] [Full Text] [Related]
13. [Treatment for multiple sclerosis in patients with collagen diseases]. Kohriyama T; Ochi K Nihon Rinsho; 2015 Sep; 73 Suppl 7():234-40. PubMed ID: 26480706 [No Abstract] [Full Text] [Related]
14. [Multiple sclerosis]. Offenhäusser M; Martin R Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627 [No Abstract] [Full Text] [Related]
15. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)]. Zavalishin IA; Zhuchenko TD; Peresedova AV Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422 [TBL] [Abstract][Full Text] [Related]